Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children.
about
Vaccines for measles, mumps and rubella in childrenDo childhood vaccines cause thrombocytopenia?Frequently asked questions on seven rare adverse events following immunization.Use of Fixed Effects Models to Analyze Self-Controlled Case Series Data in Vaccine Safety Studies.The ITP syndrome: pathogenic and clinical diversity.Idiopathic immune-mediated thrombocytopenia and recent vaccination in dogs.A scan statistic for identifying optimal risk windows in vaccine safety studies using self-controlled case series designVaccine administration and the development of immune thrombocytopenic purpura in childrenClinical practice: immune thrombocytopenia in paediatrics.Immune thrombocytopaenic purpura: an autoimmune cross-link between infections and vaccines.Adversomics: the emerging field of vaccine adverse event immunogeneticsA pragmatic framework for single-site and multisite data quality assessment in electronic health record-based clinical researchAdverse Events Following Measles, Mumps, and Rubella Vaccine in Adults Reported to the Vaccine Adverse Event Reporting System (VAERS), 2003-2013Sex-based differences in immune function and responses to vaccination.Pharmacovigilance in children: detecting adverse drug reactions in routine electronic healthcare records. A systematic review.Physicians' confidence in vaccine safety studiesSurveillance of adverse events following immunization with meningococcal group C conjugate vaccine: Tuscany, 2005-2012Vaccine Safety Surveillance Systems: Critical Elements and Lessons Learned in the Development of the US Vaccine Safety Datalink's Rapid Cycle Analysis Capabilities.Use of the self-controlled case-series method in vaccine safety studies: review and recommendations for best practice.Active surveillance for adverse events following immunization.Immunization Coverage Among Juvenile Justice Detainees.Adverse events following immunization: real causality and myths.A vaccine study design selection framework for the postlicensure rapid immunization safety monitoring program.Enhancing global vaccine pharmacovigilance: Proof-of-concept study on aseptic meningitis and immune thrombocytopenic purpura following measles-mumps containing vaccination.Overall conceptual framework for studying the genetics of autoimmune diseases following vaccination: a regulatory perspective.Vaccination and autoimmune diseases: is prevention of adverse health effects on the horizon?Self-controlled case series and misclassification bias induced by case selection from administrative hospital databases: application to febrile convulsions in pediatric vaccine pharmacoepidemiology.Minimizing signal detection time in postmarket sequential analysis: balancing positive predictive value and sensitivity.Immunogenicity, reactogenicity and consistency of production of a Brazilian combined vaccine against diphtheria, tetanus, pertussis and Haemophilus influenzae type bVaccines for measles, mumps and rubella in children
P2860
Q24203667-4EAFBD7C-2D74-4AFE-A9D3-E45F8CE9FC95Q24652460-A57A92A2-39E6-454D-A8A6-4F20CBA15F22Q30234430-D43FEB2E-E278-4E5D-8DE4-951F73509D5BQ30795124-D2A20DF4-95F9-43DD-842E-AE62728D10E8Q33384235-10710A04-73CE-4113-97F9-A0960526E6CAQ33398628-4735E64C-CD16-4BBD-B0F0-3C25026F717DQ33405209-578D47D2-E47C-460F-8964-0DC96D75821CQ33405328-A8710409-41C8-4FF3-8096-FE99689C7CEAQ33412475-D078AB0A-9568-48CC-89FB-1FCE3341AC28Q33414858-D4EA3D30-1126-4F50-AB30-B413E2F508D9Q33744268-6BC10591-DA00-443F-A971-7880A3F8FB54Q34301732-0A8D44B9-61BE-447D-BCF7-D5304416C351Q35661817-ECCAB17E-3A03-405E-B408-BD7287FAAC41Q35661949-9CE5EEDA-6D63-490C-82AC-5ADCB90821F1Q36125536-3B05C4B4-BB2B-43AC-B3F3-F000CD26394FQ36175636-F448630E-1282-4673-8032-9FB3D1012598Q36478305-F05498BE-44F2-4880-9E31-1F93171DC48FQ37327861-92FFAAF8-BB5F-4AB9-BCC0-388D402E6D59Q37919183-EC892A17-050E-4F47-90B0-529FA8C35C4EQ38172268-4C7C83BC-5185-49F7-8E8A-ACAC9EDC893FQ38530548-C9EB3E54-8885-402B-91A4-D4EB0A0EEE50Q38778111-09B7A86F-F999-46AD-9A33-68A595E5711DQ39029570-F356C5B8-B4E1-4E50-A726-FDA772542764Q39350135-211AAB28-457B-424F-9EB4-14185725BFD7Q41156699-538294D9-A719-4EC3-9AFB-3AA5B9ED7F03Q42361533-3A6200DE-A628-4328-BDCF-A75640256B39Q43848105-7533E7D9-9E4D-4044-97AF-1FD91D530622Q44475855-CF6F542E-02F0-4579-B51C-6778079DE7BEQ56795571-E60CAA7C-AA89-425D-AC98-BB8D668F1C08Q57272255-81318DF8-FBEE-4DC3-80A5-03332778771E
P2860
Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children.
description
2008 nî lūn-bûn
@nan
2008 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մարտին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
name
Risk of immune thrombocytopeni ...... ella immunization in children.
@ast
Risk of immune thrombocytopeni ...... ella immunization in children.
@en
type
label
Risk of immune thrombocytopeni ...... ella immunization in children.
@ast
Risk of immune thrombocytopeni ...... ella immunization in children.
@en
prefLabel
Risk of immune thrombocytopeni ...... ella immunization in children.
@ast
Risk of immune thrombocytopeni ...... ella immunization in children.
@en
P2093
P921
P356
P1433
P1476
Risk of immune thrombocytopeni ...... ella immunization in children.
@en
P2093
Eric K France
James Nordin
Jason Glanz
John P Mullooly
Kristi Yamasaki
Lisa A Jackson
Michael Marcy
Robert Davis
Robert T Chen
P304
P356
10.1542/PEDS.2007-1578
P407
P577
2008-03-01T00:00:00Z